A precious resource within healthcare is underutilized — the individual, family, and informal care team. Beyond “traditional” healthcare, clinical trials are another place where these resources have not been adequately leveraged.
On average, it costs $6,533 simply to recruit a participant for a clinical study. And post-recruitment, with almost 40-percent patient non-adherence, the average cost to replace a participant is $19,533. Notwithstanding these high-cost structures, systemic bias remains in the system where, for example, African Americans, who reflect 13% of the U.S. population, typically only comprise 5% of clinical trial participants. Addressing recruitment, administration, and non-adherence is critical in terms of cost, outcomes, and time. Although there are many reasons for both the high cost of recruitment and the low adherence rates, a significant issue raised by participants is the substantial burden of participation (e.g., many visits, time away from work or family, lengthy questionnaires, costs).
Accelerated by COVID, the delivery of these trials is beginning to evolve as technology is used to support and expedite decentralized clinical trials (“DCT”). However, these technology tools tend to benefit the trial administration rather than the trial participant.
As an example, Threat Research and AWS recently announced that they would work together to develop advanced machine learning architecture and artificial intelligence models to automate processes…reduc[ing] inefficiencies, and [allowing] auto-populat[ion of] data workflows that are currently performed manually. And ConcertAI’s software has reduced the time for study design and clinical trial execution by up to 25%.
While these are exciting developments, a recent survey identified that virtual trial platforms, relationship management portals, and patient experience platforms still had only 5%-6% adoption rates by study sponsors. We can impact clinical trials by focusing on a broader range of participants and support networks.
While DCTs begin to blur geographic constraints by reducing the need for participants to travel to study sites, travel is not the only impediment. Here are some relatively simple ways to use technology to ease the DCT process and bring more health equity to the system.
By increasing the focus on the participant and their care team, the overall experience can be changed. A more approachable trial is created, appealing to a broader and more diverse participant pool more reflective of society:
Addressing the immediate and indirect needs of trial participants is critical to the evolution of DCT and the more efficient and equitable delivery of clinical trials.
Need a hand? Not sure where to start?
We're here and happy to help. Drop us a line and we'll get back to you or call Support at (877) 694-4431.
We also have tons of articles and videos on our help page for many frequently asked questions.